Invesaro

Stocks TRDA Earnings

Earnings

Entrada Therapeutics, Inc. (TRDA) earnings

Quarterly results of Entrada Therapeutics, Inc. as filed with the SEC: revenue, net income and earnings per share for each of the last 8 quarters, the latest results release and when the next one is expected.

Free, no password. An email when TRDA files with the SEC.

Next earnings date

Entrada Therapeutics, Inc. is expected to report around January 7, 2027. That is an estimate from its filing rhythm (a year after the same report last year), not a date the company has announced.

Latest quarter: Q3 FY2026

In Q3 FY2026 (ended September 30, 2026) Entrada Therapeutics, Inc. reported revenue of $905K (-43.9% on the same quarter a year earlier) and a net loss of $39.7M.

Diluted earnings per share were -$0.94.

Filed with the SEC on November 5, 2026.

Revenue by quarter
Q4 24: $37.4M $37.4M Q4 24Q1 25: $20.6M $20.6M Q1 25Q2 25: $2M $2M Q2 25Q3 25: $1.6M $1.6M Q3 25Q4 25: $1.3M $1.3M Q4 25Q1 26: $875K $875K Q1 26Q2 26: $898K $898K Q2 26Q3 26: $905K $905K Q3 26
Net income by quarter
Q4 24: $1.1M $1.1M Q4 24Q1 25: -$17.3M -$17.3M Q1 25Q2 25: -$43.1M -$43.1M Q2 25Q3 25: -$44.1M -$44.1M Q3 25Q4 25: -$39.2M -$39.2M Q4 25Q1 26: -$39.7M -$39.7M Q1 26Q2 26: -$42.8M -$42.8M Q2 26Q3 26: -$39.7M -$39.7M Q3 26

Quarter by quarter

QuarterEndedRevenuevs year agoNet incomeEPS
Q3 FY2026September 30, 2026$905K-43.9%-$39.7M-$0.94
Q2 FY2026June 30, 2026$898K-53.9%-$42.8M-$1.01
Q1 FY2026March 31, 2026$875K-95.7%-$39.7M-$0.95
Q4 FY2025December 31, 2025$1.3M-96.5%-$39.2M-
Q3 FY2025September 30, 2025$1.6M--$44.1M-$1.06
Q2 FY2025June 30, 2025$2M--$43.1M-$1.04
Q1 FY2025March 31, 2025$20.6M--$17.3M-$0.42
Q4 FY2024December 31, 2024$37.4M-$1.1M-

Fourth quarters are the fiscal year minus the first three, as most companies report no separate Q4 figures.

Results filings

When is Entrada Therapeutics, Inc.'s next earnings date?

Entrada Therapeutics, Inc. is expected to report around January 7, 2027. That is an estimate from its filing rhythm (a year after the same report last year), not a date the company has announced.

What were Entrada Therapeutics, Inc.'s latest quarterly results?

For Q3 FY2026, which ended September 30, 2026, Entrada Therapeutics, Inc. reported revenue of $905K and a net loss of $39.7M. The figures come from its filing with the SEC.

Is Entrada Therapeutics, Inc.'s revenue growing?

Revenue in Q3 FY2026 was $905K, down 43.9% from $1.6M in the same quarter a year earlier.

Get an email when TRDA reports

Follow TRDA and we email you its next results the day they are filed, with the numbers explained.

Free, no password. An email when TRDA files with the SEC.

Source: quarterly figures Entrada Therapeutics, Inc. tags in its 10-Q and 10-K filings (SEC EDGAR XBRL). Not investment advice.

Everything about Entrada Therapeutics, Inc.